Can Fite Biopharma

Company snapshot

Can Fite Biopharma is a biotech organization headquartered in RAMAT GAN, L3, USA. It trades on NYSE under ticker CANF. Primary therapeutic focus areas include Plaque Psoriasis, Rheumatoid Arthritis, Hepatocellular Carcinoma, Plaque psoriasis, Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis. NovaPharmaNews links 20 clinical program(s), 0 drug profile(s), and 23 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (13), phase 3 (7).

• 20 active pipeline program(s) linked via ClinicalTrials.gov.
• 23 US patent(s) indexed to this assignee profile.
• 20 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Can Fite Biopharma. Not investment advice.

• Peer + 0 momentum

  Vertex Pharmaceuticals (Australia)

  TA overlap score 40

• Peer + 0 momentum

  Universal Integrated

  TA overlap score 37.8

• Peer + 0 momentum

  Coherus Oncology

  TA overlap score 35

• Peer + 0 momentum

  Chinese University of

  TA overlap score 28.4

Recent activity

Latest pipeline, patent, and corporate events for Can Fite Biopharma.

1. Jun 8, 2026 Clinical update

   Piclidenoson — Phase 2

2. Jun 5, 2026 Clinical update

   Namodenoson, Matching placebo for namodenoson — Phase 2

3. Jun 5, 2026 Clinical update

   Matching Placebo for Piclidenoson, Piclidenoson — Phase 3

4. Jun 5, 2026 Clinical update

   Namodenoson — Phase 2

5. Jun 5, 2026 Clinical update

   CF102 — Phase 2

View all clinical trial activity →

• What is Can Fite Biopharma?

  Can Fite Biopharma is a biotech organization headquartered in RAMAT GAN, L3, USA. It trades on NYSE under ticker CANF. Primary therapeutic focus areas include Plaque Psoriasis, Rheumatoid Arthritis, Hepatocellular Carcinoma, Plaque psoriasis, Non-Alcoholic Steatohepatitis (NASH)

• Is Can Fite Biopharma publicly traded?

  Yes. Can Fite Biopharma is listed with ticker CANF on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Can Fite Biopharma develop or market?

  We link 4 drug profile(s) where Can Fite Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/can-fite-biopharma#company-drugs.

• What are the latest developments for Can Fite Biopharma?

  In the last 12 months our linked public records show 20 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Can Fite Biopharma focus on?

  Can Fite Biopharma focuses on Plaque Psoriasis, Rheumatoid Arthritis, Hepatocellular Carcinoma based on our analysis of their pipeline programs and drug development activities.